We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Kronos Bio Inc | NASDAQ:KRON | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.04 | 1.03 | 1.04 | 2,003 | 13:21:58 |
The fireside chats will be available on the Investors & Media section of the company’s website at www.kronosbio.com. A replay of the webcasts will be archived and available for one month following each event.
About Kronos Bio, Inc.Kronos Bio is a biopharmaceutical company that is advancing two investigational compounds in clinical trials for patients with cancer. The company is developing the CDK9 inhibitor KB-0742 as a treatment for MYC-amplified solid tumors and other transcriptionally addicted solid tumors and lanraplenib, a next-generation SYK inhibitor, for patients with FLT3-mutated acute myeloid leukemia. The company’s scientific focus is on developing medicines that target the deregulated transcription that is the hallmark of cancer and other serious diseases.
Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit www.kronosbio.com or follow the company on LinkedIn.
Company Contact:Sarah Connors, Vice President of Investor Relations and Corporate CommunicationsKronos Bio857-290-7305sconnors@kronosbio.com
Investors:Leo VartorellaArgot Partners212-600-1902kronosbio@argotpartners.com
Media:Georgia West/David RosenArgot Partners212-600-1494kronosbio@argotpartners.com
1 Year Kronos Bio Chart |
1 Month Kronos Bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions